Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and
pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult
participants with relapsed/refractory solid tumors and to identify the recommended Phase 2
dose (RP2D).